The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Mixed-phenotype acute leukemia treated with decitabine

  • Lee, Ji-Young (Division of Hematology/Oncology, Department of Internal Medicine, Inje University Busan Paik Hospital) ;
  • Lee, Sang-min (Division of Hematology/Oncology, Department of Internal Medicine, Inje University Busan Paik Hospital) ;
  • Lee, Ja-Young (Department of Laboratory Medicine, Inje University Busan Paik Hospital) ;
  • Kim, Ki-Hyang (Division of Hematology/Oncology, Department of Internal Medicine, Inje University Busan Paik Hospital) ;
  • Choi, Moon-Young (Division of Hematology/Oncology, Department of Internal Medicine, Inje University Busan Paik Hospital) ;
  • Lee, Won-Sik (Division of Hematology/Oncology, Department of Internal Medicine, Inje University Busan Paik Hospital)
  • Received : 2014.11.18
  • Accepted : 2015.04.04
  • Published : 2016.03.01
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Steensma DP. Oddballs: acute leukemias of mixed phenotype and ambiguous origin. Hematol Oncol Clin North Am 2011;25:1235-1253. https://doi.org/10.1016/j.hoc.2011.09.014
  2. Matutes E, Pickl WF, Van't Veer M, et al. Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. Blood 2011;117:3163-3171. https://doi.org/10.1182/blood-2010-10-314682
  3. Garcia-Manero G, Thomas DA, Rytting ME, et al. Final report of a phase 1 trial of decitabine with or without hyperCVAD in relapsed acute lymphocytic leukemia. Blood 2010;116:867.
  4. Burke MJ, Lamba JK, Pounds S, et al. A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia. Am J Hematol 2014;89:889-895. https://doi.org/10.1002/ajh.23778
  5. Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012;30:2670-2677. https://doi.org/10.1200/JCO.2011.38.9429

Cited by

  1. Decitabine : Mild oral mucositis: case report vol.1599, pp.1, 2016, https://doi.org/10.1007/s40278-016-16950-x
  2. Therapy for children and adults with mixed phenotype acute leukemia: a systematic review and meta-analysis vol.32, pp.7, 2016, https://doi.org/10.1038/s41375-018-0058-4
  3. Venetoclax Combined with Hypomethylating Agents for Treatment-Naïve B/Myeloid Mixed Phenotype Acute Leukemia vol.2021, pp.None, 2016, https://doi.org/10.1155/2021/6661109